{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:04:13Z","timestamp":1793714653287,"version":"4.6.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA176785"],"award-info":[{"award-number":["CA176785"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA192393"],"award-info":[{"award-number":["CA192393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA225662"],"award-info":[{"award-number":["CA225662"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH Specialized Program of Research Excellence in Breast Cancer","award":["CA116201"],"award-info":[{"award-number":["CA116201"]}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ambry Genetics Inc","id":[{"id":"https:\/\/ror.org\/051ae8e94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The germline cancer predisposition genes associated with increased risk of each clinical subtype of breast cancer, defined by estrogen receptor (ER), progesterone receptor (PR), and HER2, are not well defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 54\u2009555 invasive breast cancer patients with 56 480 breast tumors were subjected to clinical hereditary cancer multigene panel testing. Heterogeneity for predisposition genes across clinical breast cancer subtypes was assessed by comparing mutation frequencies by gene among tumor subtypes and by association studies between each tumor subtype and reference controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mutations in 15 cancer predisposition genes were detected in 8.6% of patients with ER+\/HER2-; 8.9% with ER+\/HER2+; 7.7% with ER-\/HER2+; and 14.4% of ER-\/PR-\/HER2- tumors. BRCA1, BRCA2, BARD1, and PALB2 mutations were enriched in ER- and HER2- tumors; RAD51C and RAD51D mutations were enriched in ER- tumors only; TP53 mutations were enriched in HER2+ tumors, and ATM and CHEK2 mutations were enriched in both ER+ and\/or HER2+ tumors. All genes were associated with moderate (odds ratio &amp;gt; 2.00) or strong (odds ratio\u2009&amp;gt;\u20095.00) risks of at least one subtype of breast cancer in case-control analyses. Mutations in ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D, and TP53 had predicted lifetime absolute risks of at least 20.0% for breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Germline mutations in hereditary cancer panel genes confer subtype-specific risks of breast cancer. Combined tumor subtype, age at breast cancer diagnosis, and family history of breast and\/or ovarian cancer information provides refined categorical estimates of mutation prevalence for women considering genetic testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djaa023","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T07:15:44Z","timestamp":1582010144000},"page":"1231-1241","source":"Crossref","is-referenced-by-count":103,"title":["The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort"],"prefix":"10.1093","volume":"112","author":[{"given":"Chunling","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C","family":"Polley","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-9903","authenticated-orcid":false,"given":"Siddhartha","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Lilyquist","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermela","family":"Shimelis","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Na","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7714-2734","authenticated-orcid":false,"given":"Steven N","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Goldgar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Shah","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9807-4304","authenticated-orcid":false,"given":"Tina","family":"Pesaran","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill S","family":"Dolinsky","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"LaDuca","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-9985","authenticated-orcid":false,"given":"Fergus J","family":"Couch","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA"},{"name":"Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"issue":"5","key":"2020121415434017900_djaa023-B1","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2020121415434017900_djaa023-B2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-015-3612-z","article-title":"Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials","volume":"154","author":"Regan","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"2020121415434017900_djaa023-B3","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2015.64.3171","article-title":"Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials","volume":"34","author":"Regan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9472","key":"2020121415434017900_djaa023-B4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"issue":"33","key":"2020121415434017900_djaa023-B5","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020121415434017900_djaa023-B6","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/annonc\/mds067","article-title":"Targeting triple-negative breast cancer: optimising therapeutic outcomes","volume":"23","author":"Gelmon","year":"2012","journal-title":"Ann Oncol"},{"issue":"11","key":"2020121415434017900_djaa023-B7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2020121415434017900_djaa023-B8","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"2020121415434017900_djaa023-B9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","volume":"110","author":"Shimelis","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"2020121415434017900_djaa023-B10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.30498","article-title":"A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"2020121415434017900_djaa023-B11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2020121415434017900_djaa023-B12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020121415434017900_djaa023-B13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-012-2375-z","article-title":"Prevalence of germline TP53 mutations in HER2+ breast cancer patients","volume":"139","author":"Rath","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"s2","key":"2020121415434017900_djaa023-B14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1525-1438.2006.00694.x","article-title":"Association between the CHEK2*1100delC germ line mutation and estrogen receptor status","volume":"16","author":"de Bock","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"2020121415434017900_djaa023-B15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10549-011-1635-7","article-title":"Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer","volume":"132","author":"Domagala","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"2020121415434017900_djaa023-B16","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","article-title":"Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer","volume":"4","author":"Kurian","year":"2018","journal-title":"JAMA Oncol"},{"key":"2020121415434017900_djaa023-B17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2018.2956","article-title":"Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"2020121415434017900_djaa023-B18","first-page":"1","article-title":"Quality of clinician-reported cancer history when ordering genetic testing","author":"LaDuca","year":"2018","journal-title":"J Clin Oncol Inform"},{"issue":"11","key":"2020121415434017900_djaa023-B19","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum Mutat"},{"issue":"5","key":"2020121415434017900_djaa023-B20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2020121415434017900_djaa023-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2469523","article-title":"Beyond DNA: an integrated and functional approach for classifying germline variants in breast cancer genes","volume":"2016","author":"Pesaran","year":"2016","journal-title":"Int J Breast Cancer"},{"issue":"7616","key":"2020121415434017900_djaa023-B22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"key":"2020121415434017900_djaa023-B23","volume-title":"Content Analysis: An Introduction to Its Methodology","author":"Krippendorff","year":"2004"},{"issue":"3","key":"2020121415434017900_djaa023-B24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","article-title":"Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort","volume":"133","author":"Masciari","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2020121415434017900_djaa023-B25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/cncr.26377","article-title":"Early onset HER2-positive breast cancer is associated with germline TP53 mutations","volume":"118","author":"Melhem-Bertrandt","year":"2012","journal-title":"Cancer"},{"key":"2020121415434017900_djaa023-B26"},{"issue":"1","key":"2020121415434017900_djaa023-B27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic risk scores for prediction of breast cancer and breast cancer subtypes","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"7","key":"2020121415434017900_djaa023-B28","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw302","article-title":"Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 Mutation Carriers","volume":"109","author":"Kuchenbaecker","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2020121415434017900_djaa023-B29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"15","key":"2020121415434017900_djaa023-B30","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaa023\/32618633\/djaa023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/112\/12\/1231\/34899962\/djaa023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/112\/12\/1231\/34899962\/djaa023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T15:44:05Z","timestamp":1607960645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/112\/12\/1231\/5753953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,4,24]]},"published-print":{"date-parts":[[2020,12,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaa023","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,4,24]]}}}